Cubist Systematic Strategies’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-186,952
| Closed | -$3.52M | – | 3358 |
|
|
2024
Q4 | $3.52M | Sell |
186,952
-367,435
| -66% | -$6.45M | 0.02% | 1032 |
|
|
2024
Q3 | $8.34M | Buy |
+554,387
| New | +$9.48M | 0.05% | 560 |
|
|
2024
Q2 | – | Sell |
-134,282
| Closed | -$3.92M | – | 3772 |
|
|
2024
Q1 | $3.92M | Buy |
134,282
+96,337
| +254% | +$2.96M | 0.02% | 1126 |
|
|
2023
Q4 | $1.28M | Sell |
37,945
-94,053
| -71% | -$2.75M | 0.01% | 1853 |
|
|
2023
Q3 | $4.05M | Buy |
131,998
+116,889
| +774% | +$4.21M | 0.03% | 892 |
|
|
2023
Q2 | $605K | Sell |
15,109
-60,505
| -80% | -$2.5M | ﹤0.01% | 2274 |
|
|
2023
Q1 | $3.09M | Sell |
75,614
-109,059
| -59% | -$4.34M | 0.02% | 1321 |
|
|
2022
Q4 | $7.13M | Buy |
184,673
+158,481
| +605% | +$7.71M | 0.04% | 727 |
|
|
2022
Q3 | $1.39M | Buy |
26,192
+16,229
| +163% | +$902K | 0.01% | 2340 |
|
|
2022
Q2 | $581K | Sell |
9,963
-908
| -8% | -$59.5K | ﹤0.01% | 2938 |
|
|
2022
Q1 | $830K | Sell |
10,871
-51,798
| -83% | -$3.45M | 0.01% | 2184 |
|
|
2021
Q4 | $3.77M | Buy |
62,669
+5,536
| +10% | +$305K | 0.04% | 851 |
|
|
2021
Q3 | $3.2M | Buy |
57,133
+11,117
| +24% | +$641K | 0.04% | 717 |
|
|
2021
Q2 | $2.79M | Buy |
46,016
+22,746
| +98% | +$1.44M | 0.03% | 877 |
|
|
2021
Q1 | $1.63M | Sell |
23,270
-13,958
| -37% | -$997K | 0.02% | 1185 |
|
|
2020
Q4 | $2.23M | Sell |
37,228
-22,172
| -37% | -$1.3M | 0.03% | 880 |
|
|
2020
Q3 | $3.57M | Buy |
59,400
+6,534
| +12% | +$380K | 0.05% | 570 |
|
|
2020
Q2 | $2.77M | Buy |
52,866
+17,926
| +51% | +$749K | 0.05% | 607 |
|
|
2020
Q1 | $1.17M | Sell |
34,940
-23,946
| -41% | -$995K | 0.03% | 735 |
|
|
2019
Q4 | $2.67M | Buy |
58,886
+20,086
| +52% | +$853K | 0.05% | 594 |
|
|
2019
Q3 | $1.48M | Sell |
38,800
-17,478
| -31% | -$698K | 0.03% | 778 |
|
|
2019
Q2 | $2.45M | Buy |
56,278
+9,022
| +19% | +$383K | 0.05% | 596 |
|
|
2019
Q1 | $1.8M | Buy |
47,256
+30,527
| +182% | +$1.19M | 0.06% | 490 |
|
|
2018
Q4 | $720K | Buy |
16,729
+13,731
| +458% | +$641K | 0.03% | 733 |
|
|
2018
Q3 | $147K | Sell |
2,998
-3,667
| -55% | -$159K | 0.01% | 1505 |
|
|
2018
Q2 | $214K | Buy |
6,665
+6,336
| +1,926% | +$219K | 0.01% | 1307 |
|
|
2018
Q1 | $10K | Sell |
329
-4,304
| -93% | -$153K | ﹤0.01% | 1773 |
|
|
2017
Q4 | $211K | Buy |
4,633
+2,133
| +85% | +$84.5K | 0.01% | 1498 |
|
|
2017
Q3 | $94K | Sell |
2,500
-694
| -22% | -$27.9K | 0.01% | 1641 |
|
|
2017
Q2 | $152K | Buy |
3,194
+1,752
| +121% | +$81.3K | 0.01% | 1369 |
|
|
2017
Q1 | $66K | Sell |
1,442
-4,998
| -78% | -$216K | ﹤0.01% | 1444 |
|
|
2016
Q4 | $208K | Buy |
+6,440
| New | +$215K | 0.02% | 1240 |
|
|
2016
Q3 | – | Sell |
-3,974
| Closed | -$134K | – | 1818 |
|
|
2016
Q2 | $134K | Sell |
3,974
-1,774
| -31% | -$87.2K | 0.01% | 1449 |
|
|
2016
Q1 | $305K | Sell |
5,748
-5,152
| -47% | -$301K | 0.02% | 973 |
|
|
2015
Q4 | $837K | Sell |
10,900
-10,699
| -50% | -$606K | 0.05% | 559 |
|
|
2015
Q3 | $888K | Buy |
21,599
+17,854
| +477% | +$1.09M | 0.04% | 645 |
|
|
2015
Q2 | $265K | Sell |
3,745
-5,851
| -61% | -$461K | 0.01% | 1288 |
|
|
2015
Q1 | $853K | Buy |
9,596
+5,798
| +153% | +$588K | 0.04% | 657 |
|
|
2014
Q4 | $337K | Buy |
3,798
+2,961
| +354% | +$280K | 0.02% | 1129 |
|
|
2014
Q3 | $81K | Sell |
837
-665
| -44% | -$64.7K | ﹤0.01% | 1578 |
|
|
2014
Q2 | $138K | Buy |
+1,502
| New | +$114K | 0.01% | 1271 |
|
Other funds holding PCRX
DPCM
Cubist Systematic Strategies's PCRX Position: Q1 2025 in Review
Cubist Systematic Strategies sold out of Pacira BioSciences (PCRX) in Q1 2025, closing a stake of 186,952 shares — an estimated $3.52M sold.
Cubist Systematic Strategies first reported a position in PCRX in Q2 2014 and held it in 41 quarters. The position peaked at $8.34M in Q3 2024. 235 funds tracked by Wall St. Rank hold PCRX as of Q1 2025.
- Cubist Systematic Strategies reported no remaining Pacira BioSciences position as of Q1 2025 after selling out during the quarter.
- Cubist Systematic Strategies sold 186,952 Pacira BioSciences shares in Q1 2025, an estimated $3.52M.
- Cubist Systematic Strategies first reported a position in Pacira BioSciences in Q2 2014 and held it in 41 quarters.
- Cubist Systematic Strategies's Pacira BioSciences position peaked at $8.34M in Q3 2024.
- 235 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2025.
Based on Cubist Systematic Strategies's 13F filing for Q1 2025, filed 15 May 2025.